{"id":4392,"date":"2019-03-07T11:22:10","date_gmt":"2019-03-07T05:52:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4392"},"modified":"2021-07-24T12:57:13","modified_gmt":"2021-07-24T07:27:13","slug":"the-business-cocktail-57","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57","title":{"rendered":"Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a314673c5e49\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a314673c5e49\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57\/#Biogen_to_buy_Nightstar_for_USD_800_Million\" >Biogen to buy Nightstar for USD 800\nMillion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57\/#Pacira_acquires_Myoscience\" >Pacira acquires Myoscience<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57\/#Horizon_Pharma_plc_announces_pricing_of_public_offering_of_its_ordinary_shares\" >Horizon Pharma plc announces pricing\nof public offering of its ordinary shares<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57\/#A_new_joint_venture_of_STAT_with_Slingshot_Insights\" >A new joint venture of STAT with Slingshot\nInsights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57\/#Epizyme_announces_Equity_Offering\" >Epizyme announces Equity Offering<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biogen_to_buy_Nightstar_for_USD_800_Million\"><\/span><strong>Biogen to buy Nightstar for USD 800\nMillion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Biogen<\/strong> known for its efforts in treatments of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-progressive-multiple-sclerosis-ppms-market\">multiple sclerosis <\/a><\/strong>and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-sma-market-insight-epidemiology-and-market-forecast\">spinal muscular atrophy<\/a><\/strong> wound up the deal to buy <strong>Nightstar. <\/strong>The deal will let Biogen have access to two experimental gene therapies for blindness-causing diseases helping Biogen\u2019s pipeline. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pacira_acquires_Myoscience\"><\/span><strong>Pacira acquires Myoscience<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Pacira Pharmaceuticals<\/strong> is going to acquire <strong>Myoscience,<\/strong> a medical device making company, as announced by the later in its press release for up to <strong>USD 220 Million<\/strong>. The deal is good news for patients and physicians who are looking for effective <strong>non-<a href=\"https:\/\/www.delveinsight.com\/report-store\/opioid-dependence-market\">opioid <\/a>treatment<\/strong>. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Horizon_Pharma_plc_announces_pricing_of_public_offering_of_its_ordinary_shares\"><\/span><strong>Horizon Pharma plc announces pricing\nof public offering of its ordinary shares <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Horizon Pharma plc <\/strong>focused on researching and developing innovative medicines, announced the pricing of its underwritten public offering of 12,244,898 of its ordinary shares at a price of USD 24.50 per share making an offering size of up to <strong>USD 300 Million<\/strong>. The company will use the proceeds to repay USD 550 Million of outstanding debt.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"A_new_joint_venture_of_STAT_with_Slingshot_Insights\"><\/span><strong>A new joint venture of STAT with Slingshot\n<\/strong><strong>Insights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>STAT<\/strong>, a national life sciences news\norganization, has partnered with <strong>Slingshot\nInsights<\/strong>&#8211; the first crowd-funded\nexpert network and due diligence community focused on health care, to launch a\nnew service to connect health care investors with subject matter experts and\ntop-tier industry reporters called <strong>STAT<\/strong>\n<strong>Expert Advantage. <\/strong><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Epizyme_announces_Equity_Offering\"><\/span><strong>Epizyme announces Equity Offering<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Epizyme (EPZM) <\/strong>announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series-a Convertible Preferred Stock. Epizyme has granted the underwriters a 30-day option to purchase them. The net proceeds expected to be around USD 150 Million will be used to fund global development and for the commercialization of <strong><g class=\"gr_ gr_5 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling\" id=\"5\" data-gr-id=\"5\">tazemetostat<\/g>.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen to buy Nightstar for USD 800 Million Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar. The deal will let Biogen have access to two experimental gene therapies for blindness-causing diseases helping Biogen\u2019s pipeline. Pacira acquires Myoscience Pacira Pharmaceuticals is going to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4397,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[830,1867,257,2740,1497,2737,2738,2739,2736,477,2742,1580,2741,1866,2700],"industry":[17225],"therapeutic_areas":[17229,17238],"class_list":["post-4392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biogen","tag-epizyme","tag-gene-therapies","tag-horizon","tag-multiple-sclerosis","tag-myoscience","tag-nightstar","tag-non-opioid-treatment","tag-pacira","tag-pipeline","tag-slingshot-insights","tag-stat","tag-stat-expert-advantage","tag-tazemetostat","tag-usd","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-genetic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biogen buys Nightstar; Pacira acquires Myoscience; Horizon announces<\/title>\n<meta name=\"description\" content=\"Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen buys Nightstar; Pacira acquires Myoscience; Horizon announces\" \/>\n<meta property=\"og:description\" content=\"Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-07T05:52:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1598\" \/>\n\t<meta property=\"og:image:height\" content=\"1339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen buys Nightstar; Pacira acquires Myoscience; Horizon announces","description":"Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57","og_locale":"en_US","og_type":"article","og_title":"Biogen buys Nightstar; Pacira acquires Myoscience; Horizon announces","og_description":"Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-03-07T05:52:10+00:00","article_modified_time":"2021-07-24T07:27:13+00:00","og_image":[{"width":1598,"height":1339,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57","name":"Biogen buys Nightstar; Pacira acquires Myoscience; Horizon announces","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png","datePublished":"2019-03-07T05:52:10+00:00","dateModified":"2021-07-24T07:27:13+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-57#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png","width":1598,"height":1339,"caption":"mRNA"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project-300x251.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epizyme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Horizon<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myoscience<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nightstar<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">non-opioid treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pacira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Slingshot Insights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">STAT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">STAT Expert Advantage<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">tazemetostat<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USD<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biogen<\/span>","<span class=\"advgb-post-tax-term\">Epizyme<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapies<\/span>","<span class=\"advgb-post-tax-term\">Horizon<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis<\/span>","<span class=\"advgb-post-tax-term\">Myoscience<\/span>","<span class=\"advgb-post-tax-term\">Nightstar<\/span>","<span class=\"advgb-post-tax-term\">non-opioid treatment<\/span>","<span class=\"advgb-post-tax-term\">Pacira<\/span>","<span class=\"advgb-post-tax-term\">Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Slingshot Insights<\/span>","<span class=\"advgb-post-tax-term\">STAT<\/span>","<span class=\"advgb-post-tax-term\">STAT Expert Advantage<\/span>","<span class=\"advgb-post-tax-term\">tazemetostat<\/span>","<span class=\"advgb-post-tax-term\">USD<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 7, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 7, 2019 11:22 am","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4392"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4392\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4397"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4392"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4392"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}